Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Lung Cancer Research Studies, and HER2/EGFR in Cancer Research.
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial.
Supplementary Figure S3 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Supplementary Figure S2 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Supplementary Table S7 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Supplementary Table S9 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Supplementary Table S4 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Supplementary Table S3 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Supplementary Figure S4 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Supplementary Table S5 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Supplementary Figure S1 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Supplementary Table S10 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Supplementary Table S6 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Supplementary Methods S1 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Supplementary Table S8 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Supplementary Table S1 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Supplementary Table S2 from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Data from A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
Leveraging the Expertise of the CTSA Program to Increase the Impact and Efficiency of Clinical Trials
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol
Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma
Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors
Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).
Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness